Cargando…

Purulent Bronchitis Complicating Measles and Rubella

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Red Cross Society in France for the Medical Officers of the American Expeditionary Forces, 1918-1919 1919
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10211118/ https://www.ncbi.nlm.nih.gov/pubmed/37757233

Ejemplares similares

Influenza and Purulent Bronchitis
Publicado: (1918)

Differential Diagnosis of Scarlet Fever, Measles and Rubella
Publicado: (1919)

1148. Long-term Persistence of Measles and Rubella Virus Neutralizing Antibody Levels among Adults with Three Doses of Measles-Mumps-Rubella Vaccine
por: Alonge, Oluwakemi, et al.
Publicado: (2023)

2467. Timeliness of Childhood Vaccination With the Combination Measles–Mumps–Rubella–Varicella Vaccine vs. the Separate Measles–Mumps–Rubella and Varicella Vaccines in the United States
por: Wolfson, Lara, et al.
Publicado: (2018)

Two-dose measles–rubella vaccine schedule for measles–rubella elimination
por: John, T. Jacob
Publicado: (2023)

Predictors of Measles and Rubella Serostatus in Mother–Infant Pairs in Rural Nepal
por: Murray, Alastair, et al.
Publicado: (2017)

1209. Seroprevalence of Measles, Mumps, and Rubella in Korean Healthcare Workers and Strategy for Vaccination
por: Ju Choo, Eun, et al.
Publicado: (2019)

2771. Seroprotection against Measles, Rubella, Tetanus, and Diphtheria Among Children in Haiti—2017
por: Minta, Anna A, et al.
Publicado: (2019)

Difficulties in Eliminating Measles and Controlling Rubella and Mumps: A Cross-Sectional Study of a First Measles and Rubella Vaccination and a Second Measles, Mumps, and Rubella Vaccination
por: Wang, Zhifang, et al.
Publicado: (2014)

Measles and rubella microarray array patches to increase vaccination coverage and achieve measles and rubella elimination in Africa
por: Richardson, Lauren Christine, et al.
Publicado: (2020)

Accelerating the Development of Measles and Rubella Microarray Patches to Eliminate Measles and Rubella: Recent Progress, Remaining Challenges
por: Hasso-Agopsowicz, Mateusz, et al.
Publicado: (2022)

Genetic Characterization of Measles and Rubella Viruses Detected Through Global Measles and Rubella Elimination Surveillance, 2016–2018
por: Brown, Kevin E., et al.
Publicado: (2019)

Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran
por: Saffar, Hana, et al.
Publicado: (2021)

1171. Measles and Rubella Seroprevalence among HIV-infected and uninfected Children and Adults in Zambia
por: Yang, Yangyupei, et al.
Publicado: (2021)

Measles, Mumps, and Rubella Antibody: Patterns of Persistence and Rate of Decline Following the Second Dose of the MMR Vaccine
por: Seagle, Emma, et al.
Publicado: (2017)

2762. A Cohort Analysis of Completion of the Pediatric Measles-Mumps-Rubella-Varicella Series in the United States
por: Wolfson, Lara J, et al.
Publicado: (2019)

2763. Uptake and Safety of Measles-Mumps-Rubella (MMR) Vaccine in Adolescents and Adults in the Vaccine Safety Datalink
por: Hanson, Kayla E, et al.
Publicado: (2019)

1339 Measles and Mumps Antibody Response in Young Adults after a Third Dose of Measles-Mumps-Rubella Vaccine
por: Fiebelkorn, Amy Parker, et al.
Publicado: (2014)

Measles & rubella outbreaks in Maharashtra State, India
por: Vaidya, Sunil R., et al.
Publicado: (2016)

Rubella and Its Relations to Scarlet Fever and Measles
Publicado: (1908)

2017 Measles-Rubella Vaccination Campaign in India
por: Shrivastava, Saurabh RamBihariLal, et al.
Publicado: (2018)

Expansion of the measles and rubella laboratory network, India
por: Sharma, Deepa, et al.
Publicado: (2022)

Modified measles versus rubella versus atypical measles: One and same thing
por: Gupta, Surender Nikhil, et al.
Publicado: (2015)

Cord Blood Antibody Seroprevalance Against Diphtheria, Pertussis, Measles, Mumps and Rubella among Term Healthy Indian Newborns
por: James, Deepak, et al.
Publicado: (2017)

571. A Report of the Postmarketing Spontaneous Safety Data over 24 Years for GSK’s Measles-Mumps-Rubella (MMR) Vaccine
por: Singh, Tina, et al.
Publicado: (2022)

The impact of Measles-Rubella vaccination on the morbidity and mortality from Congenital Rubella Syndrome in 92 countries
por: Vynnycky, Emilia, et al.
Publicado: (2018)

Mass Measles Rubella Immunization Campaign: Bhutan Experience
por: Giri, Bhakta R, et al.
Publicado: (2011)

Measles, Mumps, Rubella serology in juvenile idiopathic arthritis
por: Heijstek, MW, et al.
Publicado: (2008)

Characterizing the dynamics of rubella relative to measles: the role of stochasticity
por: Rozhnova, Ganna, et al.
Publicado: (2013)

Strengthening routine immunization through measles-rubella elimination
por: Biellik, Robin J., et al.
Publicado: (2018)

Measles-Rubella vaccination campaign: A trust deficit?
por: Sreedevi, A
Publicado: (2018)

Is it time to reconsider measles, mumps, and rubella immunisation strategies?
por: Boccalini, Sara, et al.
Publicado: (2021)

Measles-Mumps-Rubella Vaccine and COVID-19 Relationship
por: Özdemir, Öner
Publicado: (2020)

Towards elimination of measles and rubella in Italy: Progress and challenges
por: Adamo, Giovanna, et al.
Publicado: (2019)

Cost of conducting Measles-Rubella vaccination campaign in India
por: Chatterjee, Susmita, et al.
Publicado: (2021)

Immunogenicity of measles-rubella vaccine administered under India’s Universal Immunization Programme in the context of measles–rubella elimination goal: A longitudinal study
por: Verma, Santosh Kumar, et al.
Publicado: (2023)

Purulent Arthritis Complicating Smallpox
por: Wallace, E. H., et al.
Publicado: (1939)

Positive Method of Preventing and Curing Purulent Infection
Publicado: (1916)

Early Onset Optic Neuritis Following Measles-Rubella Vaccination
por: Moradian, Siamak, et al.
Publicado: (2008)

Resurgence risk for measles, mumps and rubella in France in 2018 and 2020
por: Béraud, Guillaume, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oq40qmvpsvhanna5bfqer30q29